Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway | Zendy

Zhenghuan Fang | Zendy; Kyung Hee Jung | Zendy; Hong Yan | Zendy; Soo-Jung Kim | Zendy; Marufa Rumman | Zendy; Jung Hee Park | Zendy; Boreum Han | Zendy; Ji Eun Lee | Zendy; Yeo Wool Kang | Zendy; Joo Han Lim | Zendy; Soon Sun Hong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway

Author(s) -

Zhenghuan Fang,

Kyung Hee Jung,

Hong Yan,

Soo-Jung Kim,

Marufa Rumman,

Jung Hee Park,

Boreum Han,

Ji Eun Lee,

Yeo Wool Kang,

Joo Han Lim,

Soon Sun Hong

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000491058

Subject(s) - sorafenib , melatonin , cancer research , pancreatic cancer , medicine , in vivo , stat3 , pharmacology , receptor tyrosine kinase , signal transduction , apoptosis , tyrosine kinase , cancer , receptor , biology , hepatocellular carcinoma , microbiology and biotechnology , biochemistry

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignant tumors with poor prognosis. Conventional chemotherapies including gemcitabine have failed owing to weak response and side effects. Hence novel treatment regimens are urgently needed to improve the therapeutic efficacy. In this study, we aimed to assess the anticancer activity of melatonin and sorafenib as a novel therapy against PDAC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research